Signals, Powered By EquityPandit
American pharmaceuticals firm Eli Lilly and Company have announced that it has issued royalty-free, non-exclusive voluntary licences to Cipla, Lupin and Sun Pharmaceutical Industries Ltd, who are collaborating with the company to accelerate and expand the availability of baricitinib in India.
Apart from these established Indian pharmaceutical manufacturers of generic medicines, Lilly is also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licences.
Lilly recently received permission for restricted emergency use by the Central Drugs Standard Control Organization (CDSCO), ministry of health, for baricitinib to be used in combination with remdesivir for the treatment of suspected or laboratory-confirmed covid-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
These voluntary licensing agreements will ensure high-quality manufacturing and accessibility of baricitinib during this pandemic, improving the local treatment options available to positively impact the lives of people who are currently battling covid-19 in India, the company said in a statement.
“Lilly is committed to supporting India in this healthcare challenge through our innovative and effective portfolio of breakthrough medicines. During the current surge in a covid-19 pandemic, we have responded by issuing three voluntary licences for baricitinib by pharmaceutical companies in India to accelerate its local manufacturing and distribution under best quality conditions,” Luca Visini, managing director, India subcontinent, Lilly India, said.
“More licences to additional Indian generic manufacturers are expected to be announced soon. This is in addition to the donations being offered by Lilly to the Indian government that will potentially help alleviate the burden of covid-19. We will continue to explore other possible initiatives to support patients and the healthcare system in India,” said Visini.
Stock Covered in the news
Cipla Ltd-View Detailed Analysis
